Although business headlines still tout earnings numbers, many investors have moved past net earnings as a measure of a company’s economic output. That’s because earnings are very often less trustworthy than cash flow, since earnings are more open to manipulation based on dubious judgment calls.
Earnings’ unreliability is one of the reasons Foolish investors often flip straight past the income statement to check the cash flow statement. In general, by taking a close look at the cash moving in and out of the business, you can better understand whether the last batch of earnings brought money into the company, or merely disguised a cash gusher with a pretty headline.
Calling all cash flows
When you are trying to buy the market’s best stocks, it’s worth checking up on your companies’ free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That’s what we do with this series. Today, we’re checking in on Clear Channel Outdoor Holdings (NYSE: CCO ) , whose recent revenue and earnings are plotted below.
Best Managed Healthcare Companies To Buy Right Now: Pimco High Income Fund(PHK)
PIMCO High Income Fund is a closed ended fixed income mutual fund launched and managed by Allianz Global Investors Fund Management LLC. The fund is co-managed by Pacific Investment Management Company LLC. It invests in the public fixed income markets across the globe. The fund invests in U.S. dollar denominated high-yield corporate debt obligations. It employs fundamental analysis along with a top down stock picking approach to make its investments. PIMCO High Income Fund was formed on April 30, 2003 and is domiciled in the United States.
- [By Dan Caplinger]
But you can see in several places the consequences of the stampede toward high yield. Here are just a few:
Closed-end funds Cornerstone Progressive (NYSEMKT: CFP ) and Pimco High Income (NYSE: PHK ) both make fixed payments back to fund shareholders on a monthly basis, and their distribution yields are truly extraordinary, at about 17% and 12%, respectively. Those dividends have enticed shareholders to pay $1.30 to $1.40 or more for each $1 of assets in the funds. Yet during most months, a substantial portion of those distribution payments has simply been a return of investor capital rather than true income from the funds’ investments. A recent study discussed in The Wall Street Journal found that returns on a portfolio with a combined value and dividend-income strategy outperformed a strategy focused more exclusively on maximizing dividends by an average of 1.7 percentage points per year, a huge edge in long-run returns. In the dividend ETF arena, most funds tend to focus on maximizing yield. Although the popular Vanguard Dividend Appreciation (NYSEMKT: VIG ) ETF bucks the trend by screening first for consistent dividend growth and only then looking at yield as a factor, many rival ETFs start with high-yielding stocks as their baseline and only then consider other desirable traits. Others focus solely on high-dividend niches of the market, such as iShares FTSE NAREIT Mortgage-Plus (NYSEMKT: REM ) and its concentration on high-yield mortgage REITs.
When dividend stocks get too popular, their prices get out of line with both their dividend income and the fundamentals of the businesses that underlie those stocks. In simpler terms, when dividend stocks become bad values, it’s time to consider looking elsewhere for a margin of safety.
- [By Dan Caplinger]
Lesson 1: Income is king.
A look at the four funds trading at the highest premiums to net asset value reveals a common thread: They’re all focused on maximizing income. What’s interesting, though, is that they use different methods to reach the same ends. Among the three PIMCO funds, PIMCO High Income (NYSE: PHK ) looks largely to the high-yield bond market for its holdings, while PIMCO Corporate & Income Opportunities (NYSE: PTY ) has a somewhat lower distribution rate but has a sizable allocation to investment-grade debt. The fund with the highest premium, PIMCO Global StocksPLUS, uses futures contracts to add stock exposure to its portfolio of income-producing bonds. Finally, BlackRock Virginia Municipal Bond rounds out the top four with its tax-free bond portfolio.
- [By Morgan Housel]
Interest rates have risen over the last month, offering a taste. Pimco High Income Fund (NYSE: PHK ) is down 10% in the last month. The Vanguard Long Term Corporate Bond Fund (NASDAQ: VCLT ) lost 4.6%. Mortgage REITS sensitive to the same interest rate risk have been pummeled; Annaly Capital Management (NYSE: NLY ) shares are off by one-fifth over the last year.
Best Managed Healthcare Companies To Buy Right Now: LogMein Inc.(LOGM)
LogMeIn, Inc. provides on-demand, remote-connectivity, collaboration, and support solutions to small and medium-sized businesses, information technology (IT) service providers, mobile carriers, and consumers in the United States and internationally. Its services include remote user access services, which allow users to access computers and other Internet-enabled devices to continue working while away from the office or to access personal systems while away from home; remote support and management services to deliver support and management of IT resources remotely; and remote collaboration to conduct online meetings and share documents, images, and their desktop with other users. The company?s remote user access services comprise LogMeIn Free, a free remote access service, which provides secure access to a remote computer or other Internet-enabled device; LogMeIn Pro, a remote access service; LogMeIn Hamachi, a hosted virtual private network service; and LogMeIn Ignition, a service that delivers access to remote computers that subscribe to LogMeIn Free or LogMeIn Pro. Its remote support and management services consist of LogMeIn Rescue, a Web-based remote support service to support remote computers and applications, and assist computer users via the Internet; LogMeIn Rescue+Mobile, an add-on of LogMeIn Rescue?s Web-based remote support service to remotely access and support smartphones and tablet computers; LogMeIn Central, a Web-based management console; and LogMeIn Backup, a service that subscribers install on two or more computers to create a backup network. The company?s remote collaboration services include join.me and join.me pro, which are browser-based online meetings and screen sharing services. LogMeIn, Inc. has a strategic agreement with Intel Corporation. The company was formerly known as 3am Labs, Inc. and changed its name to LogMeIn, Inc. in March 2006. LogMeIn, Inc. was founded in 2003 and is headquartered in Woburn, Massachu se tts.
- [By Rich Smith]
This series, brought to you by Yahoo! Finance, looks at which upgrades and downgrades make sense and which ones investors should act on. Today, our headlines feature upgrades for mini-industrialist Stratasys (NASDAQ: SSYS ) and for remote computer access specialist LogMeIn (NASDAQ: LOGM ) but a downgrade for publicly traded soccer club Manchester United (NYSE: MANU ) . Let’s take them one at a time, beginning with…
- [By Rich Smith]
Remote-access software maker LogMeIn (NASDAQ: LOGM ) reported strong Q1 earnings Thursday evening, beating analyst estimates on both profits and revenues, and guiding investors to expect higher-than-consensus earnings for both Q2 and the full year. LogMeIn said it earned $0.12 per share in the fiscal first quarter, will earn $0.11 to $0.12 in Q2, and keep on that track, with about $0.48 per share at the midpoint of guidance for the year.
- [By Brian Pacampara]
What: Shares of software company LogMeIn (NASDAQ: LOGM ) soared 21% today after its quarterly results and outlook topped Wall Street expectations.
- [By Rich Smith]
This series, brought to you by Yahoo! Finance, looks at which upgrades and downgrades make sense, and which ones investors should act on. Today, we’re focusing on tech stocks, as analysts pull back on Facebook (NASDAQ: FB ) and Dolby Labs (NYSE: DLB ) , but become more bullish on LogMeIn (NASDAQ: LOGM ) . Let’s start with that last one.
Best Managed Healthcare Companies To Buy Right Now: Smart Ventures Inc (SMVR)
Smart Ventures, Inc., incorporated on November 22, 2006, is an exploration-stage company. The Company focuses on exploring, acquiring, developing and producing mineral reserves. The Company had purchased certain mineral claims located in the Laurentides Region near Mont Laurier, Quebec. In June 2011, the Company acquired Metal Assets S.A. In February 2014, Smart Ventures Inc announced the closing of its acquisition of The Sanday Corporation oil and gas drilling Services Company.
As of December 31, 2009, the Company had not generated any revenues. The Company focuses on establishing and exploiting deposits of both base and precious metals.
- [By Peter Graham]
Small cap marijuana stocks Smart Ventures Inc (OTCMKTS: SMVR) and Vitamin Blue Inc (OTCMKTS: VTMB) jumped 40.28% and 38.6%, respectively, while hemp stock Astika Holdings Inc (OTCBB: ASKH) fell 13.75% on Friday. Moreover, only one of these small cap stocks seems to have been the subject of a few paid promotions or investor relations types of activities. So will all three of these marijuana or hemp stocks keep producing highs or lows for investors and traders alike? Here is a quick reality check:
Smart Ventures Inc (OTCMKTS: SMVR) Plans to Enter the Marijuana Edibles Business
Small cap Smart Ventures Inc is an independent energy company engaged in engineering extended reach drilling services, acquisition, development, production, and exploration of oil, gas and minerals internationally. On Friday, Smart Ventures Inc rose 40.28% to $0.07 for a market cap of $2.31 million plus SMVR is up 600% over the past year and down 93.3% in intermittent trading since December 2009 according to Google Finance.
Best Managed Healthcare Companies To Buy Right Now: Galena Biopharma Inc (GALE)
Galena Biopharma, Inc. (Galena), formerly RXi Pharmaceuticals Corporation, incorporated on April 3, 2006, is a biotechnology company focused on discovering, developing and commercializing therapies addressing unmet medical needs using targeted biotherapeutics. The Company is pursuing the development of cancer therapeutics using peptide-based immunotherapy products, including its main product candidate, NeuVaxTM (E75), for the treatment of breast cancer and other tumors. NeuVax is a peptide-based immunotherapy intended to reduce the recurrence of breast cancer in low-to-intermediate HER2-positive breast cancer patients not eligible for trastuzumab (Herceptin; Genentech/Roche). On January 19, 2012, the Company initiated enrollment in its Phase 3 PRESENT clinical trial for NeuVax (E75 peptide plus GM-CSF) vaccine in low-to-intermediate HER2 1+ and 2+ breast cancer patients in the adjuvant setting to prevent recurrence (Clinicaltrials.gov identifier NCT01479244). The Preventio n of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVax Treatment study is a randomized, multicenter, multinational clinical trial that will enroll approximately 700 breast cancer patients. The Company’s Phase 2 trial of NeuVax achieved its primary endpoint of disease-free survival (DFS). On April 13, 2011, the Company completed its acquisition of Apthera, Inc.,(Apthera).
The Company focuses to start a Phase 2 trial comparing NeuVax in combination with trastuzumab (Herceptin) versus trastuzumab, alone, in a 300-patient, randomized study in the adjuvant breast cancer setting. The Company’s second product candidate, Folate Binding Protein-E39 (FBP), is a vaccine, consisting of the peptides E39 and J65, aimed at preventing the recurrence of ovarian, endometrial, and breast cancers. On February 14, 2012, the Company announced the initiation of a Phase 1/2 clinical trial in two gynecological cancers: ovarian and endometrial adenocarcinomas. Folate binding protein has ! very limited tissue distribution and expression in non-malignant tissue and is over-expressed in more than 90% of ovarian and endometrial cancers, as well as in 20% to 50% of breast, lung, colorectal and renal cell carcinomas.
In April 2011, the Company acquired Apthera Inc and its NeuVax product candidate. The Company focuses on developing a pipeline of immunotherapy product candidates for the treatment of various cancers based on the E75 peptide, the advanced of which is NeuVax, which is targeted at preventing the recurrence of breast cancer. NeuVax has had positive Phase 1/2 clinical trial results for the prevention of breast cancer recurrence in patients who have had breast cancer and received the standard of care treatment (surgery, chemotherapy, radiotherapy and hormonal therapy as indicated). The Company had also initiated its Phase 3 PRESENT clinical trial of NeuVax for the prevention of breast cancer recurrence in early-stage low-to-intermediate HER2 br east cancer patients. NeuVax directs killer T-cells to target and destroy cancer cells that express HER2/neu, a protein associated with epithelial tumors in breast, ovarian, pancreatic, colon, bladder and prostate cancers. NeuVax is comprised of a HER2/neu-derived peptide called E75. E75 is a nine-amino acid sequence that is immunogenic (produces an immune response) and GM-CSF is a commercially available protein that acts to stimulate and activate components of the immune system such as macrophages and dendritic cells.
The Company also develops novel applications for NeuVax based on preclinical studies and phases 2 clinical trials which suggest that combining NeuVax and trastuzumab (Herceptin; Genentech/Roche) can increase antigen presentation by tumor cells by promoting receptor internalization and subsequent proteosomal degradation of the HER2 protein. The Company also is pursuing additional therapeutic indications for NeuVax that are in Phase 1/2 clinical tri als. RXI-109, is a dermal anti-scarring therapy that targets! connecti! ve tissue growth factor (CTGF) and that may inhibit connective tissue formation in human fibrotic disease.
The Company competes with Roche Laboratories, Inc., Pfizer Inc., Bayer HealthCare AG, Sanofi-Aventis, US, LLC, Amgen, Inc., GlaxoSmithKline plc, Renovo Group plc, CoDa Therapeutics, Inc., Sirnaomics, Inc., FirstString Research, Inc., Merz Pharmaceuticals, LLC, Capstone Therapeutics, Halscion, Inc., Garnet Bio Therapeutics, Inc., AkPharma Inc., Promedior, Inc., Kissei Pharmaceutical Co., Ltd., Eyegene, Derma Sciences, Inc., Healthpoint Biotherapeutics, Pharmaxon, Excaliard Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Inc., Marina Biotech, Inc., Tacere Therapeutics, Inc., Benitec Limited, OPKO Health, Inc., Silence Therapeutics plc, Quark Pharmaceuticals, Inc., Rosetta Genomics Ltd., Lorus Therapeutics, Inc., Tekmira Pharmaceuticals Corporation, Arrowhead Research Corporation, Regulus Therapeutics Inc. and Santaris.
- [By James E. Brumley]
The last two weeks have been absolutely fantastic ones for Galena Biopharma Inc. (NASDAQ:GALE). Shares have soared from $2.37 to the current price of $3.32 – a 40% pop – rewarding investors who had been patiently waiting through late October for the runup to take hold. Congratulations if that’s you. But, if that was you, then now might be a great time to take the money and run with the trade, as GALE looks poised to make a sizeable pullback. More on that in a moment.
- [By James E. Brumley]
It may look like little more than a choppy mess with just a quick glance at Galena Biopharma Inc. (NASDAQ:GALE). But, the more you study the chart – and the company – the more you realize there’s enough long-term potential from the company’s pipeline to keep spurring GALE in a generally-upward direction. In fact, the bulls look like they’re on the verge of taking Galena Biopharma out of second gear and putting it into third. As such, it may not be a bad bet at this point.
- [By Sean Williams]
The waiting game
The tables are clearly stacked against small biotech companies developing cancer drugs. History has shown that few (if any) have successfully had the Food and Drug Administration approve a late-stage cancer drug. While mid-stage trials of Galena Biopharma’s (NASDAQ: GALE ) HER2-targeting breast cancer vaccine have been promising thus far, the chances of an approval seem a long way off.
Best Managed Healthcare Companies To Buy Right Now: Commonwealth Bank of Australia (CBA)
Commonwealth Bank of Australia (the Bank) is engaged in the provision of a range of banking and financial products and services to retail, small business, corporate and institutional clients. The Bank is a provider of integrated financial services, including retail, business and institutional banking, superannuation, life insurance, general insurance, funds management, broking services and finance company activities. Its operating segments include Retail Banking Services, Business and Private Banking, Institutional Banking and Markets, Wealth Management, New Zealand, Bankwest and Other. Its retail banking services include home loans, consumer finance, retail deposits and distribution. Its business and private banking include corporate financial services, regional and agribusiness banking, local business banking, private bank and equities and margin lending. The Bank and its subsidiaries ceased to be a substantial holder in Ten Network Holdings Limited, as of September 12, 201 2. Advisors’ Opinion:
- [By Jan Schalkwijk]
M-Pesa, the system that revolutionized mobile payments in Kenya and beyond, is not capital intensive for Safaricom, but the company has to pay 10% of revenues to Vodafone, which runs the system’s technology backbone. Safaricom is planning to take this job on itself going forward, which should increase profitability, though there would be some operational risk if they can’t deliver the same level of service. M-Pesa has now spawned M-Shwari, which is the same concept but adds mobile banking services such as the provision of credit. This new service is delivered in partnership with the unlisted Commercial Bank of Africa (CBA).
- [By Yoshiaki Nohara]
Panasonic Corp., Japan’s largest consumer electronics maker, climbed 6.8 percent after posting profit that beat estimates. STX Offshore & Shipbuilding Co. (067250) jumped 15 percent in Seoul after agreeing to restructure it debt. Commonwealth Bank of Australia (CBA), the nation’s biggest lender, fell 1.5 percent, pacing losses among the nation’s financial shares on a report the government will impose a new tax on banks.
Best Managed Healthcare Companies To Buy Right Now: Bellway PLC (BWY)
Bellway p.l.c. is a United Kingdom-based holding company, owning subsidiary undertakings, which is engaged principally in housebuilding in the United Kingdom. The Company’s subsidiaries include Bellway Homes Limited, Bellway Properties Limited, Bellway (Services) Limited, Litrose Investments Limited, Bellway Financial Services Limited, Bellway Housing Trust Limited and The Victoria Dock Company Limited. Advisors’ Opinion:
- [By Sofia Horta e Costa]
Bellway Plc (BWY) added 1.4 percent after the homebuilder said reservations in the past four months rose 31 percent as buyers had greater access to mortgages. Elan (ELN) Corp. jumped to a 10-month high in Dublin after Royalty Pharma increased its offer for the Irish drugmaker to as much as $6.7 billion. BT Group increased 3.7 percent as Barclays Plc recommended investors buy shares of the U.K.’s largest fixed-line company.
- [By Sofia Horta e Costa]
Persimmon dropped 4.3 percent to 1,061 pence, while Bellway Plc (BWY) declined 3.1 percent to 1,262 pence. Bovis Homes Group Plc slipped 2.7 percent to 712 pence. Chancellor of the Exchequer George Osborne and the Bank of England will reassess the Help-to-Buy program, which allows the purchase of homes with a deposit as small as 5 percent, every September from 2014, the Treasury said.
Best Managed Healthcare Companies To Buy Right Now: Titan Pharmaceuticals Inc (TTNP.OB)
Titan Pharmaceuticals, Inc., incorporated in February 1992, is a biopharmaceutical company developing therapeutics primarily for the treatment of central nervous system (CNS) disorders. The Company is focused primarily on clinical development of products that include Probuphine for the treatment of opioid addiction; Iloperidone: for the treatment of schizophrenia and related psychotic disorders, and Spheramine for the treatment of advanced Parkinson’s disease. Titan Pharmaceuticals is directly developing its product candidates and also utilizing corporate partnerships, including a collaboration with Bayer Schering Pharma AG, Germany (Bayer Schering) for the development of Spheramine to treat Parkinson’s disease, and Vanda Pharmaceuticals, Inc. (Vanda) for the development of iloperidone for the treatment of schizophrenia and related psychotic disorders.
Probuphine is the first product to utilize the Company’s ProNeura long-ter m drug delivery technology. Probuphine is designed to provide continuous, long-term therapeutic levels of the drug buprenorphine, an approved agent for the treatment of opioid addiction. In December 2007, the Company completed enrollment in a randomized, double-blind, placebo-controlled, multi-center Phase III clinical study of Probuphine in the treatment of opioid addiction. This 150 patient study, which is being conducted in the United States, will evaluate the safety and effectiveness of treatment with Probuphine versus placebo in reducing opioid addiction over 24 weeks of treatment. This study is part of a registration directed program intended to obtain marketing approval of Probuphine for the treatment of opioid addiction in Europe and the United States.
Iloperidone was evaluated in a Phase III program comprising over 3,500 patients at more than 200 sites in 24 countries, administered and funded by Novartis Pharma AG (Novartis). In three completed efficacy studies conducted by Novartis, ! i! loperidone statistically reduced the symptoms of schizophrenia compared to placebo. Iloperidone has also been investigated in three 12-month safety studies, which confirm safety and tolerability. A dose dependent increase in the Q-T Corrected (QTc) interval was observed and investigated further in a clinical study, and no clinically significant adverse events were observed. In September 2007, Vanda submitted a new drug application (NDA) with the United States Food and Drug Administration (FDA) for iloperidone. The NDA for iloperidone was officially accepted for review by the FDA in November 2007.
Spheramine is a cell-based therapeutic that utilizes the Company’s cell-coated microcarrier (CCM) technology, which enables the development of cell-based therapies for minimally invasive, site-specific delivery to the central nervous system of therapeutic factors precisely where they are needed. Spheramine consists of microcarriers coated wit h human retinal pigment epithelial cells that are intended to enhance brain levels of dopamine, a neurotransmitter deficient in certain brain regions in Parkinson’s disease, leading to movement disorders. Preclinical studies have demonstrated the preliminary efficacy and safety of Spheramine, including blinded studies in a primate model of Parkinson’s disease. In June 2007, enrollment was completed in a current multi-center, randomized, double-blind, placebo-controlled clinical trial of Spheramine in Parkinson’s disease. This Phase IIb clinical study enrolled 71 patients with advanced Parkinson’s disease (Hoehn and Yahr Stages III and IV) to further evaluate the efficacy, safety, and tolerability of Spheramine.
Bayer Schering, the Company’s corporate partner for worldwide development and commercialization of Spheramine, is funding the clinical development program for Spheramine. Under an agreement, Bayer Schering has received exclusive, worldwide deve lopment, manufacturing and commercialization rights, an! d, in! ad! dition! to the clinical and manufacturing development funding and milestone payments, Bayer Schering will pay Titan Pharmaceuticals a royalty on future product sales.
- [By C.R. Jackson]
Fanapt was discovered by Hoechst Marion Roussel in 1995 as a novel atypical antipsychotic agent. Hoechst was a German life-sciences company that became Aventis Deutschland after its merger with France’s Rhône-Poulenc in 1999. When the company joined with Sanofi-Synthélabo in 2004, it became a subsidiary of the Sanofi-Aventis (SNY) the French pharmaceutical conglomerate. In 1997, Hoechst sold the research rights to Titan Pharmaceuticals (TTNP.OB). Then Titan quickly sold the worldwide rights to Novartis in 1998. Novartis then sold the Phase 3 development rights for loperidone to Vanda in 2004. Vanda originally attempted to get FDA approval for Fanapt in 2008, but the FDA refused to approve iloperidone. The agency required an additional clinical trial.
Best Managed Healthcare Companies To Buy Right Now: Alere Inc (ALR)
Alere Inc., incorporated on May 11, 2001, is a provider of point-of-care diagnostics and services. The Company’s products and services help healthcare practitioners make treatment decisions and improve outcomes for individuals living with chronic disease. The Company’s portfolio also includes a range of health information solutions that access to critical health data, provide clinical decision support, and facilitate performance reporting and analysis. The Company’s segment includes professional diagnostics, health information solutions and consumer diagnostics. The Company distributes its professional diagnostic products to hospitals, reference laboratories, physician offices and other point-of-care settings through an worldwide distribution networks. In February 2013, the Company acquired Epocal, Inc.
Professional diagnostics are generally designed to assist medical professionals in both preventative and interventiona l medicine, and include testing and monitoring performed in hospitals, laboratories and doctors’ offices and, increasingly, patient self-testing, which the Company defines as testing or monitoring performed at home under the supervision of a medical professional. Professional diagnostic products provide for qualitative or quantitative analysis of patient samples for evidence of a specific medical condition, disease state or toxicological state or to measure response to therapy. The point-of-care market for rapid diagnostic products includes all areas where a patient is assessed or diagnosed, including hospitals, laboratories, physician offices, specialized mobile clinics, emergency rooms, rapid-response laboratories and patient health screening locations.
The Company’s Alere Cholestech LDX System is a point-of-care monitor of blood cholesterol and related lipids which is used to test patients at risk of, or suffering from, heart disease and related conditions. T he Alere Cholestech LDX System makes it possible to provide ! a complete lipid profile with tests for total cholesterol, high-density lipoprotein cholesterol (HDL) and low-density lipoprotein cholesterol (LDL), triglycerides, and glucose. The Company’s Alere INRatio System is an easy-to-use, hand-held blood coagulation monitoring system for use by patients and healthcare professionals in the management of warfarin, a commonly prescribed medication used to prevent blood clots. The Company also offers the epoc Blood Analysis System for bloods gas, electrolyte and metabolite testing, which is manufactured by its recently acquired Epocal division. The epoc (enterprise point-of-care) platform is a point-of-care analysis system which provides Wireless bedside blood gas, electrolyte and metabolite measurement testing solutions and complements the Company’s Alere Triage products in cardiology and emergency room settings.
The Company develops and markets a range of point-of-care tests for influenza A/B, RSV, strep throat, pneumonia , C. difficile, infectious mononucleosis, HIV, herpes simplex virus (HSV-2), hepatitis C (HCV), hepatitis B (HBV), malaria, lyme disease, Chlamydia, H. pylori, rubella and other infectious diseases. The Company’s tests for infectious disease are sold under brand names that include Alere, Alere Determine, Acceava, BinaxNOW, Clearview, DoubleCheckGold, Panbio, SD, TECHLAB and Alere TestPack. In addition to point-of-care products, the Company also offers a line of indirect fluorescent antibody, or IFA, assays for over 20 viral, bacterial and autoimmune diseases, a full line of serology diagnostic products covering a range of disease categories and over 50 enzyme-linked immunosorbent assay (ELISA), tests for a range of infectious and autoimmune diseases, as well as a full line of automated instrumentation for processing ELISA tests.
The Company offers laboratory-based testing services throughout Europe under the name Alere Toxicology, formerly Concateno, and in the United States under the names Alere Toxicology Services, or! Alere To! xicology, and Redwood Toxicology Laboratory, or Redwood. The Company offers point-of-care diabetes products, including its Afinion Analyzer System and its NycoCard System. The Company’s Alere Connect products include HealthPAL and HealthCOM.
Health Information Solutions
The Company’s health information solutions are designed to provide physicians with actionable data that allows them to make more decisions in real time, deliver quality care, and put the individuals they treat on a pathway to better health. The Company offers a range of software-based analytics, clinical decision support tools, and accountable cares programs that enable healthcare providers to initiate earlier interventions, personalize treatment plans, lower costs by reducing hospital readmissions, and measure improvements in outcomes at both a patient and population level. With this range of scalable solutions, the Company is able to support healthcare practitioners in the transit ion to accountable care, as well as in meeting the new pay-for-performance guidelines set by the Centers for Medicare & Medicaid Services (CMS).
The Company’s Women’s and Children’s Health division delivers a range of obstetrical care services that range from risk assessments focused on identifying women who may experience pregnancy complications to a neonatal program that supports early infant care management. The Company offers home-based obstetrical monitoring for pregnant women with medical or pregnancy-related problems that could puts their health or the health of their babies at risk. The Company also delivers telephonic and home-based nursing services that support improved clinical outcomes. The Company offers a suite of integrated wellness programs and resources that is designed to reduce participant health risks and healthcare-related costs. The Company’s wellness programs include screening for risk factors associated with chronic disease, particularly tobacco use, poor nutrition, physical inactivity, and chron! ic stress! .
The Company offers services designed to support anticoagulation management for patients who takes warfarin to control their risk for stroke and clotting disorders. Alere Home Monitoring, the Company’s patient self-testing business, assists patients in acquiring home INR monitors and with insurance coverage determinations and provides physicians with a comprehensive model that allows them to incorporate patient self-testing into their practices.
The Company’s consumer diagnostic products consist of the Company’s First Check brand of over-the-counter drug tests for at-home testing for up to seven illicit drugs and five prescription drugs, as well as First Check brand over-the-counter tests for cholesterol monitoring. The Company also sells Balance Activ Vaginal Gel directly to consumers and healthcare professionals for the treatment of bacterial vaginosis without antibiotics.
The Company competes with Abbott, Siemens, Beckman Coulter, Johnson & Johnson, Roche, Abaxis Medical Diagnostics, International Technidyne Corporation, INOVA Diagnostics, DiaSorin, Diamedx and Qiagen.
- [By Seth Jayson]
Calling all cash flows
When you are trying to buy the market’s best stocks, it’s worth checking up on your companies’ free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That’s what we do with this series. Today, we’re checking in on Alere (NYSE: ALR ) , whose recent revenue and earnings are plotted below.